Gilead Sciences (NASDAQ:GILD) Stock Rating Reaffirmed by Oppenheimer
Gilead Sciences (NASDAQ:GILD – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at Oppenheimer in a research note issued to investors on Friday, Benzinga reports. They currently have a $105.00 price objective on the biopharmaceutical company’s stock. Oppenheimer’s price target suggests a potential upside of 58.04% from the company’s current […]